Who to call at Oaktree Acquisition Corp. III Life Sciences, and when
Fundz watches for the moments Oaktree Acquisition Corp. III Life Sciences starts buying, and tells you who to reach.
- An alert the day Oaktree Acquisition Corp. III Life Sciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Oaktree Acquisition Corp. III Life Sciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Oaktree Acquisition Corp. III Life Sciences. With Fundz connected, it knows.
Oaktree Acquisition Corp. III Life Sciences
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.oaktreeacquisitioncorp.comAI Executive Summary
AI-powered analysis of 8-K filing content
Oaktree Acquisition Corp. III Life Sciences appointed Dr. David A. Berry, co-founder of Averin Capital, as an independent Class II director on October 17, 2025, and assigned him to the audit, nominating, and compensation committees. The appointment is a routine board change that supports the company's continued compliance with Nasdaq independent director requirements.
Key Takeaways
Dr. David A. Berry was appointed as an independent Class II director, effective October 17, 2025.
Berry was assigned to the Board's audit, nominating, and compensation committees, which broadens independent oversight of financial reporting, governance, and executive pay.
3 more takeaways
Related Filings (4)
4 more filings from Oaktree Acquisition Corp. III Life Sciences in the last 90 days
Filing Overview
What This Means
Oaktree Acquisition Corp. III Life Sciences filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.